Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 13/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623884 | 0.87 | MAP2K1 (0.52) | MAP2K1MAP2K2KDRCYP3A4CHRNA7 | |
| SCHEMBL5623838 | 0.87 | MAP2K1 (0.52) | MAP2K1MAP2K2KDRFLT1 | |
| SCHEMBL5623826 | 0.86 | MAP2K1 (0.52) | MAP2K1MAP2K2KDRCYP3A4 | |
| SCHEMBL6205699 | 0.79 | MAP2K1 (0.37) | MAP2K1MAP2K2KDRCYP3A4CHRNA7 | |
| SCHEMBL5623868 | 0.79 | MAP2K1 (0.45) | MAP2K1MAP2K2KDRFLT1 | |
| SCHEMBL5623525 | 0.78 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL6527760 | 0.75 | MAP2K1 (0.49) | MAP2K1MAP2K2KDRFLT1 | |
| SCHEMBL5622768 | 0.75 | MAP2K1 (0.49) | MAP2K1MAP2K2KDRFLT1 | |
| SCHEMBL13070495 | 0.74 | MAP2K1 (0.41) | MAP2K1MAP2K2KDRCYP3A4CHRNA7 | |
| SCHEMBL391126 | 0.74 | MAP2K1 (0.55) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273877-B2 | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2007-09-25 | — | — | US | claimed |
| US-20050026964-A1 | 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY LLC | 2005-02-03 | — | — | US | claimed |
| US-7273877-B2 | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273877-B2 | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273877-B2 | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2007-09-25 | — | — | US | disclosed |
| US-20050026964-A1 | 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY LLC | 2005-02-03 | — | — | US | disclosed |
| WO-2005000818-A1 | 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026964-A1 | 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | CYP3A5, CYP4B1, CYP3A4 | MAP2K1 4286/4885MAP2K2 3777/4885KDR 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.